The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up ...

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter ...

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a significant expansion of its manufacturing capacity through a ...

In addition, the company is constructing a brand new, state-of-the-art fill/finish manufacturing facility in Rensselaer, New York, and has acquired an over 1 million-square foot property in ...

This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol ...

The US regulator has cleared the new 8 mg formulation of Eylea (aflibercept) for patients with ... rocketed more than 500% to over $1.2 billion in the same period, with almost $900 million from ...

The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the ...